OS Therapies Announces Shelving of U.S. FDA Commissioner's National Priority Voucher Has No Impact on the Company
OST-HER2 remains eligible for Priority Review Voucher ("PRV") if approved by the U.S. Food and Drug Administration's ("FDA") on or before September 30, 2029Company continues to benefit from its UK research and development program, through which it received approximately $900,000 in non-dilutive tax creditsGrasonville, Maryland--(Newsfile Corp. - November 13, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer...